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Abstract
Background: Psychological distress (i.e. depression and anxiety) is a strong predictor of functional status and other
aspects of quality of life in autologous stem cell transplantation following high-dose chemotherapy. Treatment of
psychological distress is hypothesized to result in improvement of functional status and other aspects of quality of
life. The aim is to evaluate the outcome of stepped care for psychological distress on functional status and other
aspects of quality of life in patients with hematological malignancy treated with autologous stem cell
transplantation.
Methods/Design: The study is designed as a randomized clinical trial with 2 treatment arms: a stepped care
intervention program versus care as usual. Patients are randomized immediately pre transplant. Stepped care and
care as usual are initiated after a 6 weeks buffer period. Outcome is evaluated at 13, 30, and 42 weeks post
transplant.
In the experimental group, the first step includes an Internet-based self-help program. If psychological distress per-
sists after the self-help intervention, the second step of the program is executed, i.e. a diagnostic evaluation and a
standardized interview, yielding a problem analysis. Based on this information, a contract is made with the patient
and treatment is provided consisting of individual face-to-face counseling, medication, or referral to other services.
Care as usual comprises an interview with the patient, on ad hoc basis; emotional support and advice, on ad hoc
basis; if urgent problems emerge, the patient is referred to other services.
Primary outcome variables are psychological distress and functional status. Data are analyzed according to the
intention to treat-principle.
Discussion: This study has several innovative characteristics. First, the outcome of the intervention for
psychological distress in patients with hematological malignancy treated with autologous stem cell transplantation
is evaluated in a randomized controlled study. Second, the impact of the intervention on functional status is
evaluated: it is hypothesized that reduction of psychological distress results in improved functional status.
Furthermore, the intervention concerns an Internet-based treatment in the first step. Finally, the intervention is
characterized by an emphasis on self-management, efficiency, and a multi-disciplinary approach with nurses taking
up a central role.
Trial Registration: NTR1770
* Correspondence: a.braamse@vumc.nl
1Department of Psychiatry and EMGO Institute for Health and Care Research,
VU University Medical Center, Amsterdam, the Netherlands
Braamse et al. BMC Cancer 2010, 10:361
http://www.biomedcentral.com/1471-2407/10/361
© 2010 Braamse et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Background
Psychological distress as risk factor for impaired quality
of life
Autologous stem cell transplantation (auto-SCT) follow-
ing high-dose chemotherapy is acknowledged as one of
the most stressful treatments in anti-cancer therapy.
Previous research documented strong decreases of
health-related quality of life during and directly after
auto-SCT, with gradual improvement during the first
year of follow up [1]. Three to five years after transplan-
tation, most patients report a good health-related quality
of life. However, when compared to age- and gender-
standardized values of the general population, their
health-related quality of life is still decreased [1], in par-
ticular with respect to functional status, symptoms,
social function, and other aspects of quality of life.
Psychological distress has shown to be the strongest
predictor of health-related quality of life apart from
relapse in cancer patients following auto-SCT [2-5]. Dis-
tress is generally defined as ‘a multi-determined unplea-
sant emotional experience of a psychological (cognitive,
behavioral, emotional), social, and/or spiritual nature that
may interfere with the ability to cope effectively with can-
cer, its physical symptoms and its treatment. Distress
extends along a continuum, ranging from common feel-
ings of vulnerability, sadness and fears to problems that
may become disabling, such as depression, anxiety, panic,
social isolation, and spiritual crisis’ [6]. Previous research
has mainly focused on depression and anxiety as indica-
tors of psychological distress. Approximately 26-36% of
patients reports moderate to severe depressive symptoms
during the first year post transplant [7,8], 18% of patients
endorses moderate to severe anxiety within the first 100
days after transplantation [8].
Patients who suffer from depression before stem cell
transplantation, are more likely to have impaired func-
tional status post transplant [2]. Furthermore, the pre-
sence of depression and anxiety during the acute phase
of transplantation predicts functional status, social func-
tion and generic quality of life after transplantation [3].
Similar results have been reported in other studies [4,5].
With respect to depression, some previous studies
reported that depression predicts survival after auto-
SCT [9-11]. However, the influence of depression on
survival in cancer patients is under considerable debate,
as no univocal evidence supports this relationship [12].
From the existing literature we may conclude that psy-
chological distress, specifically depression and anxiety,
are predictors of functional status and other aspects of
quality of life in patients treated with auto-SCT.
Treatment of psychological distress
The findings on psychological distress being a prognos-
tic determinant of health-related quality of life provide a
strong empirical basis for an intervention focusing on
treatment of psychological distress in auto-SCT. Treat-
ing psychological distress is expected to substantially
improve functional status and other aspects of health-
related quality of life following auto-SCT.
Problem solving treatment is an effective intervention
for reducing psychological distress and improving quality
of life in cancer survivors [13-15]. Problem solving treat-
ment does not aim to directly solve patients’ problems;
instead, it aims to strengthen the self-management skills
of patients to solve present and future problems. Patients
learn to regain control of their problems and life by (a)
prioritizing problems which matter most to them and
which in principle can be solved; (b) analyzing the pro-
blem and generating alternative solutions; (c) selecting
methods for solution and implementing them; and
(d) evaluating the results and preparing for the future.
The improvement of self-management skills helps
patients to adjust to the limitations caused by their dis-
ease and to improve their quality of life, to manage their
own lives and give direction to the care they receive [16].
Patients receiving auto-SCT may therefore highly profit
from improved self-management skills.
In delivering treatment for psychological distress, the
stepped care approach has been strongly advocated
[17-19]. In this approach, patients start with the least
intensive treatment that is most likely to work, with more
intensive and costly interventions reserved for those insuf-
ficiently helped by the initial intervention. Stepped care
attempts to maximize the effectiveness and efficiency of
decisions about allocation of resources in therapy. Promis-
ing results of this approach have been documented [18].
In the present study, treatment for psychological dis-
tress, applying the stepped care approach, will be offered
to patients receiving auto-SCT for the treatment of a
hematological malignancy. Patients will receive auto-
SCT for relapsed disease or upfront. All patients will be
pretreated with (immuno-)chemotherapy. The transplant
related mortality of auto-SCT is low (<5%). Relapsed
disease occurs between 5 and 50% of the patients,
depending on their disease.
The aim of this study is to evaluate the outcome of
stepped care for psychological distress on functional sta-
tus and other aspects of quality of life in patients with
hematological malignancy treated with auto-SCT. It is
hypothesized that stepped care results in improvement
of psychological distress, and thereby in improvement of
functional status and other aspects of quality of life (see
figure 1).
Methods/Design
Design
The study is designed as a clinical trial with a random
allocation of patients into two alternative treatment
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arms: stepped care and care as usual. Patients treated
with auto-SCT are randomized immediately pre-trans-
plant (T0). Stepped care and care as usual are initiated
after a 6 weeks buffer period, allowing for initial recov-
ery post-transplant. At 13 weeks (T13), 30 weeks (T30)
and 42 weeks (T42) post-transplant, outcome is evalu-
ated. The design is illustrated in figure 2.
Setting and study sample
This will be a multicenter study in one of the large Dutch
university hospitals and a Dutch teaching hospital. Inclu-
sion criteria:(a) patients with hematological malignancy
(multiple myeloma, (non-)Hodgkin lymphoma, acute
myeloid leukemia, or acute lymphoid leukemia) treated
with auto-SCT after (immuno-)chemotherapy; and (b)
life expectation >3 months. Exclusion criteria: (c) age <18
or >65 years (65 years is included); (d) insufficient com-
mand of the Dutch language to complete questionnaires;
or, if so: no support by family or professional interpreters;
(e) contraindication for the stepped care approach; (f) no
informed consent.
Randomization and blinding
To allocate patients to either stepped care or to care as
usual, permutated-blocked randomization with stratifica-
tion for study center (university hospital versus teaching
hospital) and for diagnosis (multiple myeloma, (non-)
Hodgkin lymphoma, or acute (myeloid or lymphoid)
leukemia) made up by a random digit generator is used.
When patients have completed the baseline-question-
naire (T0), allocation will be performed by an indepen-
dent researcher (BM), who is not in contact with the
patients and keeps the randomization list in secure and
confidential custody. He gives the patient a unique ran-
domization number. The allocation will be sent by email
to the investigator (AMJB), who informs the patient.
The clinicians involved in the stepped care program will
be informed of the allocation by AMJB only after
screening for psychological distress at T13, and only if
the patient meets the criterion for psychological distress
after completion of the Internet based self-help pro-
gram, resulting in further treatment being offered.
Due to the nature of the intervention, neither patients
nor health care providers can be blinded to the
intervention. However, randomization, scoring of outcome
variables, and statistical analysis will be performed blindly.
Interventions
I. Protocol stepped care
The key-elements of the protocol for stepped care are
described below.
Step 1: Internet-based self-help program
The Dutch website “Alles onder controle” ["Everything
under control"] is used, adjusted for patients with hemato-
logical malignancy receiving auto-SCT http://www.
allesondercontrole.nu/sct. “Everything under control” is a
brief, web based intervention for problem-solving (which
is based on self-examination therapy). Both international
and national research has shown that this intervention is
effective in treating psychological distress [20,21]. The
intervention applies the principles of problem-solving
therapy, which proved to be effective in several rando-
mized controlled studies [22]. There is also evidence from
a growing number of trials showing that psychological
treatments can be effectively delivered over the Internet. A
recent meta-analysis found that the effects of Internet-
based treatments for depression and anxiety disorders are
as large as those of face-to-face treatments [23].
The intervention “Everything under control” takes
approximately five weeks in total. In that period, respon-
dents describe what they think is important in their
lives, make a list of their problems and concerns, and
divide these into three categories: important and solva-
ble problems (these are solved through a six-step proce-
dure of problem-solving); unimportant problems
(problems that are not related to what is important in
their lives); and important but unsolvable problems
(such as losing someone through death). For the impor-
tant and solvable problems, the respondent analyzes the
problem and generates alternative solutions; selects and
implements the chosen solution; and evaluates the
results and prepares for the future. For the important
but unsolvable problems, the respondent makes a plan
on how to cope with them.
Coaching will be given by one of the researchers
(AMJB). The coaching consists of brief, weekly contacts
by e-mail, which take about 10 to 15 minutes per week.
The total coaching time is 1 to 1,5 hours per respon-
dent. The coaching is not aimed at developing a patient-
therapist relationship but is only meant to give support
in working through the self-help method.
The intervention “Everything under control” is avail-
able in a booklet for those patients who do not have
access to the Internet or who prefer the booklet over
the web based therapy. The content of the booklet is
similar to the web based intervention. Coaching will be
via telephone or e-mail.
Figure 1 Stepped care, psychological distress, and quality of life.
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The intervention “Everything under control” is offered
to all patients in the experimental treatment arm: most
patients are expected to suffer from psychological dis-
tress during the acute phase of the transplant [8,24].
The self-help intervention is offered as pro-active sup-
port in coping with this psychological distress.
Diagnostic evaluation, standardized interview, and problem
analysis
After completing the Internet-based self-help program,
all patients are screened for psychological distress. In
order to cover the entire range of mood states asso-
ciated with psychological distress, three instruments will
be used measuring symptoms of psychological distress.
These instruments are the Patient Health Questionnaire
(PHQ-9), the Hospital Anxiety and Depression Scale
(HADS), and the State-Trait Anxiety Scale: state version
(STAI-state). For details on the measurement instru-
ments, see section ‘Assessment’ below.
Psychological distress is defined as a score ≥10 on the
PHQ-9, or ≥8 on the HADS (anxiety), or ≥8 on the
Figure 2 Design of the RCT.
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HADS (depression), or ≥40 on the STAI (state) (adapted
from Lee [8]).
Step 2: Contracting, individual face-to-face counseling,
medication, or referral to other services
Patients meeting the criterion for psychological distress
after completion of the Internet-based self-help program
are offered further treatment. It is expected that approxi-
mately 50% of the patients will meet this criterion [8].
A collaborative team consisting of consultant psychia-
trist, consultant psychiatric nurse, nurse practitioner
(department of hematology), hematologist and patient is
formed. The team evaluates the patient’s need for treat-
ment and develops the treatment plan. The nurse prac-
titioner coordinates the team efforts, the development of
the treatment plan and the execution of it. The team
meets to develop tentative treatment options and to
evaluate outcome of treatment.
Diagnostic evaluation is made by the consultant psychia-
trist. The anxiety and depression modules of the Compo-
site International Diagnostic Interview (CIDI) are
administered for the classification of symptoms [25]. Addi-
tionally a standardized interview is held by the consultant
psychiatric nurse, assessing the impact of distress on qual-
ity of life and the need for treatment. For this purpose, the
Camberwell Assessment of Need (CAN) is used, measur-
ing met and unmet needs on 22 domains of living [26].
The nurse practitioner and the consultant psychiatric
nurse score case complexity and resulting care needs,
using the Intermed [27,28]. Results of the diagnostic eva-
luation, standardized interview and scoring of case com-
plexity are used by the collaborative team to analyze the
existent problems, to evaluate the need for treatment and
to develop tentative treatment options. The diagnostic
evaluation, standardized interview and problem analysis
are performed in a maximum of 4 weeks.
When treatment options have been developed, the
patient is invited for an appointment with the consultant
psychiatric nurse. In this meeting, the results of the pro-
blem identification and analysis are presented, persona-
lized goals are identified and the patient is offered a
choice between several treatment options (see below).
The patient and consultant psychiatric nurse decide on
the treatment, which matches the patient’s problems,
needs and preferences (contracting). The shared deci-
sion is written down in the personalized treatment plan:
the treatment plan specifies identified problems, need
for care, personalized goals, tailored treatment, and
times for evaluation. The patient receives a copy of the
personalized treatment plan and is invited to use the
plan in staying focused on the personalized goals.
The following treatment options are available:
A) Individual face-to-face counseling Face-to-face
counseling is provided by the consultant psychiatric
nurse, with the individual treatment plan serving as a
guide. The treatment consists of problem solving treat-
ment (see above), with a maximum of six sessions. The
consultant psychiatric nurses have been thoroughly
trained in problem solving treatment, and will follow a
manual in delivering treatment [29,30]. If indicated, the
partner will be involved in counseling. This decision will
be made by the collaborative team.
B) Medication Medication is prescribed by the consul-
tant psychiatrist as needed. Suggested medication
includes, among others, SSRI’s and benzodiazepines.
Occasionally, antipsychotics or mood stabilizers may be
needed.
C) Referral If an indication exists, the team refers the
patient to health care or social services, e.g. physiother-
apy, social work, or psychotherapy.
Step 2 including contracting and implementation of
treatment options lasts for a maximum of 10 weeks.
II. Protocol care as usual
Care as usual consists of the following elements: If the
patient brings up any problem, the hematologist inter-
views the patient (on an ad hoc basis, no formal screen-
ing for distress). During regular visits to the department
of Hematology, hematologists and nurses provide emo-
tional support and advise patients on how to cope with
impairments of quality of life, on an ad hoc basis. If
urgent problems emerge, the patient is referred to other
services.
III. Contrast between interventions
A marked contrast between stepped care and care as
usual exists. Key elements of the contrast include:
- Internet-based self-help program, based on the
principles of problem solving therapy versus no self-
help program.
- Formal screening for psychological distress versus
ad hoc interview if a patient brings up any problems.
- Collaborative team (consultant psychiatrist, consul-
tant psychiatric nurse, nurse practitioner, hematolo-
gist and patient) coordinated by nurse practitioner
versus ad hoc care delivered by hematologist and
nurse.
- Diagnostic evaluation (consultant psychiatrist),
standardized interview assessing psychological dis-
tress (consultant psychiatric nurse) and problem
analysis versus non-standardized interview performed
by hematologist and nurse.
- Contracting versus no contracting.
- Individual face-to-face counseling, medication, or
planned referral to other services versus support,
advice, and referral to other services on ad hoc basis.
Assessment
Assessments are made at baseline, 13 weeks, 30 weeks
and 42 weeks post transplant.
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Sociodemographic data
The following sociodemographic data are collected: age,
gender, social status, employment, and Dutch vs. non-
Dutch origin.
Medical-somatic data
Collected medical-somatic data are: diagnosis, time from
diagnosis to auto-SCT, cancer treatment (pre-treatment,
relapse vs. first line treatment), proceeding to allogeneic
SCT within six months after auto-SCT (only in multiple
myeloma group), hematological recovery data, number
of platelet transfusions and packed cell transfusions, and
survival/relapsed disease with concomitant second/third
line treatment/death.
Main outcome variables
Psychological distress is measured by the Hospital Anxi-
ety and Depression Scale (HADS). The HADS consists
of 14 questions. There are two subscales assessing anxi-
ety and depression, respectively. The two scales can be
combined into one scale assessing psychological distress.
The HADS does not contain items which might also be
symptoms of physical illness (such as loss of appetite)
[31-33]. This instrument has shown to be reliable, valid,
and responsive, and has been widely used in research on
cancer patients (e.g. [24]).
Quality of life (primary outcome: physical role func-
tion) is measured by the European Organisation for
Research and Treatment of Cancer - Quality of Life
Questionnaire - C30 (EORTC-QLQ-C30) version 3.0.
The EORTC Quality of Life Questionnaire is an inte-
grated system for assessing the health-related quality of
life of cancer patients. The core questionnaire incorpo-
rates five functional scales (physical, role, cognitive,
emotional, and social), three symptom scales (fatigue,
pain, and nausea and vomiting), a global health status
and quality of life scale, and a number of single items
assessing additional symptoms commonly reported by
cancer patients (dyspnea, loss of appetite, insomnia, con-
stipation and diarrhea) and perceived financial impact of
the disease. The instrument has been shown to be valid,
reliable, and responsive to change [34].
Secondary outcomes
As secondary outcome variables, depression and anxiety
are assessed by the Patient Health Questionnaire (PHQ-9)
(depression) [35] and the State-Trait Anxiety Scale: state
version (STAI-state) (anxiety) [36]. To measure health-
related quality of life, the Medical Outcomes Study (MOS)
36-item Short Form Survey (SF-36) is used [37]. Other
questionnaires are the Dutch General Self-efficacy Scale
(DGSS) for measuring the belief of patients in their ability
to function independently [38], the Social Problem Solving
Skills-Revised (SPSI-R) to assess problem solving skills
[39], and the Social Support List to measure the interac-
tions and discrepancies that people experience in receiving
social support from their direct environment [25]. At 42
weeks, patients’ evaluation of care is assessed with the
‘GGZ-thermometer’, i.e. a Dutch instrument to measure
patients’ satisfaction with provided health care and with
the quality of health care services [40]. The validity and
reliability of these instruments have been described else-
where [35,36,38-44].
Diagnostic evaluation and problem analysis
The evaluation of the patient’s need for treatment prior
to step 2 is made with the following instruments. Diag-
nostic evaluation is established with the anxiety and
depression modules of the Composite International
Diagnostic Interview (CIDI) [25]. The CIDI classifies
diagnoses according to DSM-IV criteria [45]. For the
assessment of care needs, two instruments are used: the
Intermed [27,28] for assessing case complexity and
resulting care needs, and the Camberwell Assessment of
Need (CAN) [26] for detecting (un)fulfilled health and
social needs in people with mental illness.
Process of care
A checklist is used to collect data on process of care:
number of visits to an outpatient clinic, number of (re-)
admissions, length of stay, second/third line treatment,
content of stepped care (step 1 and step 2), and co-
interventions (somatic and psychological treatment).
This checklist was developed specifically for the trial.
Statistical analysis
Primary outcomes are psychological distress as mea-
sured with the HADS and physical role function as mea-
sured with the EORTC-QLQ-C30. These primary
outcomes reflect the central hypothesis of the study:
stepped care is hypothesized to result in improvement
in psychological distress, and thereby in improvement of
functional status (see figure 1). Secondary outcome mea-
sures include: other measures of psychological distress;
other aspects of quality of life; cognitions and coping.
Data are analyzed according to the intention to treat-
principle. In a secondary analysis, a per protocol analysis
will be performed. Baseline comparability of the experi-
mental and control group is evaluated with descriptive
statistics. The difference in outcome between stepped
care and care as usual is evaluated by means of (mixed
model) analysis of covariance. The randomization strata
(hospital and diagnosis) will be included as covariates.
In addition, a group*time-interaction term will be
entered into the model to test for a difference in treat-
ment effect over time. In analyzing a specific outcome
variable, the baseline score of that variable is used as
covariate.
If shown to be effective, we will explore whether
patient characteristics (diagnosis, psychological distress,
aspects of quality of life, cognition, coping, social sup-
port, and case complexity) moderate outcome of stepped
care, using analyses of interaction between patient
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characteristics and treatment (stepped care vs. care as
usual). Furthermore, we will explore which changes
mediate outcome, by analyzing whether (a) change in
psychological distress, (b) change in cognition, or (c)
characteristics of the process of care mediate the out-
come of stepped care, using the Baron and Kenny
approach towards mediation and the Sobel test.
Both the analysis of moderating factors and the analy-
sis of mediating factors is explorative in nature. This
study is powered to answer the primary research ques-
tion, i.e. the outcome of stepped care for psychological
distress on functional status.
Sample size
The power calculation concerns the comparison at T30
compared to T0 between the two groups (stepped care
vs. care as usual). A recent meta-analysis on problem
solving therapy for mental and physical health problems
has documented an effect size of d = 0.54, compared to
treatment as usual (compared to waiting list or no treat-
ment, the effect size was d = 1.37; compared to atten-
tion placebo, the effect size was d = 0.54). Setting d =
0.5, alpha = 0.05 (two tail), beta = 0.80, the required
sample size is 2 × 64 = 128 patients
A second power calculation was made concerning the
difference in treatment effect over time (T0, T13, T30,
and T42). Setting the within-subject correlation coeffi-
cient (rho) at 0.5, the required sample size following
from this calculation is 2 × 42 = 84 patients.
The exclusion rate is estimated at 30% (primarily due to
no informed consent). A detailed analysis of historical data
has shown that the loss due to inclusion in other studies
and mortality is 20%. The drop out rate is estimated at
20%. Consequently, 286 patients need to be invited for the
study. On an annual basis, 80 autologous transplants are
expected. Therefore, the inclusion period is 43 months.
Discussion
This study design has several innovative characteristics.
As to our knowledge, this is the first study in which the
outcome of an intervention for psychological distress in
patients with hematological malignancy treated with
auto-SCT is evaluated in a randomized controlled proto-
col. Auto-SCT following high dose chemotherapy is a
stressful treatment, leading to high levels of psychologi-
cal distress [1]. Psychological follow up for patients trea-
ted with auto-SCT is in general not being systematically
pursued; emotional support, advising on coping pro-
blems, and referring to other services usually occur on
an ad hoc basis. To improve the quality of care and in
order to reach more patients suffering from psychologi-
cal distress following intensive hematological cancer
treatment, it is essential to systematize and extend the
follow up care.
The intervention in our study has been developed to
improve patients’ self-management and has been tai-
lored to the needs of our specific patient group. Self-
management is intended to help patients adjust to their
condition and to improve their quality of life. The aims
are to give patients control over their life and to obtain
a proactive attitude in the patient [16]. Patients who are
treated with auto-SCT for hematological malignancy,
could therefore highly profit from improved self-
management.
Furthermore, since psychological distress is a predictor
of functional status in patients with hematological
malignancy treated with auto-SCT [2-5], it is expected
that the intervention will result in improvement of func-
tional status if the intervention is successful in reducing
psychological distress. The study is powered to evaluate
the effect of the intervention on both psychological dis-
tress and functional status. Because (immuno-)che-
motherapy and SCT have a strong impact on functional
status, improved functional status as a consequence of
reduced psychological distress would be a highly desir-
able outcome.
A third innovative characteristic of the present study
is that the intervention aims at efficiency both in efforts
and costs. This is reflected in the choice for a stepped
care program, in which patients start with the least
intensive treatment that is most likely to work, with
more intensive and costly interventions reserved for
those insufficiently helped by the initial self-help inter-
vention. It is expected that most patients will be suffi-
ciently helped by the Internet-based treatment, offered
in step 1 [8]. Since there is minimal therapist contact,
the therapist-time is being extremely reduced, the costs
are low and there is no need for a waiting list [46].
Patients can systematically work on their self-manage-
ment skills at any place and time they prefer.
Some patients will need more help than the Internet-
based self-help program can offer them and will there-
fore enter step 2. A strength of this stage of the pro-
gram is the multidisciplinary approach with a clear
distribution of tasks and the nurse accomplishing a
coordinating role. Multiple professional disciplines are
brought together to treat the patients in the aftermath
of disease. The collaborative team will evaluate the
patients’ need for treatment from various perspectives
and subsequently develop the treatment plan. This colla-
boration of the various disciplines is coordinated by a
nurse practitioner. Consequently, the professionals have
the opportunity to deliver care efficacious and effi-
ciently, and patients are assured of tailored care.
In the implementation of the stepped care program,
nurses take up a central role. Especially during the phase
of diagnostic evaluation and problem analysis, and during
step 2, the nurse’s contribution to treatment and care is
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essential. The nurse not only coordinates the collabora-
tive team efforts, the development of the treatment plan,
and the execution of it, but also assesses patients’ case
complexity and resulting care needs. Furthermore, the
problem solving treatment sessions during step 2 are pro-
vided by a consultant psychiatric nurse.
The study also has some limitations that have to be
taken into account. It could be that the most vulnerable
patients will drop out of the experimental group because
of difficulties completing the intervention program. This
could reflect selective drop-out and lead to differences
between the experimental and control group, because
participants in the control group do not have to adhere
to an intervention program, but only have to complete
questionnaires. The data will be analyzed according to
the intention to treat-principle. As a result, we will esti-
mate the effects of allocating an intervention in practice,
and not the effects in the subgroup of participants who
adhere to the program. During the study, the drop out
and (non-)compliance will be monitored. In a secondary
analysis, patients completing treatment will be analyzed
(per protocol analysis): this will allow us to estimate the
effect of the intervention as such. Another limitation
could be the length of the recruitment period. Given the
long recruitment period, changes in medical treatment
cannot be excluded. This may have impact on the inter-
vention, although it is expected that patients in the
intervention group and the control group will be
affected in the same way.
If our trial shows a successful outcome, the interven-
tion will be available for use in clinical practice. Results
of this study will be available in 2014.
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